Please login to the form below

Not currently logged in
Email:
Password:

bimagrumab

This page shows the latest bimagrumab news and features for those working in and with pharma, biotech and healthcare.

Pfizer abandons antibody for Duchenne

Pfizer abandons antibody for Duchenne

Novartis and Morphosys gave up on their bimagrumab for muscle-wasting disease sporadic inclusion body myositis two years ago, while Shire/Acceleron and Amgen have also chalked up failures in this

Latest news

  • Novartis orphan drug wins 'breakthrough' status from FDA Novartis orphan drug wins 'breakthrough' status from FDA

    Novartis orphan drug wins 'breakthrough' status from FDA. Bimagrumab could be first treatment for rare life-threatening muscle-wasting condition. ... With no effective therapies currently available for sIBM, bimagrumab has the potential to be the first

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Four Health

Beautiful things happen when you put the right ingredients together. It’s the reason that we mix behaviour change experts with...

Latest intelligence

EU
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...
Nudge-nudge, think-think
Chris Ross examines the personal complexities of human behaviour – and explains why fun, emotion and peer endorsement could be key to designing effective behavioural change programmes...
Peoples Award
Quality in Care Diabetes 2018: the best in innovative diabetes care
Awards highlight new evidence-based approaches to improving care...

Infographics